Subject(s)
Drug Approval/legislation & jurisprudence , Drug Discovery , Membrane Transport Proteins/chemistry , Neuronal Ceroid-Lipofuscinoses/drug therapy , Oligonucleotides, Antisense/therapeutic use , Technology, Pharmaceutical/legislation & jurisprudence , Alternative Splicing , Child , Female , Humans , Membrane Transport Proteins/genetics , Neuronal Ceroid-Lipofuscinoses/genetics , Risk Management , Technology, Pharmaceutical/economics , United States , United States Food and Drug AdministrationABSTRACT
Extemporaneous compounding is a means to tailor a medication to an individual patient's needs and may be required when no commercial product exists to meet that need. Compounded products range from buffered lidocaine to topical creams and ointments. Recent heightened regulations have made compounding more challenging for dermatologists and prompted this review of regulations, liability, and safety related to compounding. With this information, providers may minimize liability and maximize safety while caring for their patients.
Subject(s)
Drug Compounding , Drug Compounding/economics , Drug Compounding/standards , Drug-Related Side Effects and Adverse Reactions , Humans , Technology, Pharmaceutical/legislation & jurisprudence , United States , United States Food and Drug AdministrationABSTRACT
We make the case for why continuous pharmaceutical manufacturing is essential, what the barriers are, and how to overcome them. To overcome them, government action is needed in terms of tax incentives or regulatory incentives that affect time.
Subject(s)
Drug Industry/legislation & jurisprudence , Pharmaceutical Preparations/chemistry , Technology, Pharmaceutical/legislation & jurisprudence , Drug and Narcotic Control/legislation & jurisprudenceABSTRACT
The Health Law, Policy & Ethics Project at Emory University School of Law and the Human Toxicology Project Consortium of the Humane Society of the United States co-sponsored a symposium on October 23, 2017, to showcase innovations using human-based in silico and in vitro models for drug and device discovery. The goal of the symposium was to introduce researchers and students to exciting new tools and possible future careers that will increase understanding of disease and improve the search for effective therapeutics, while reducing reliance on animal testing. The symposium concluded with a discussion between scientists and lawyers about the legal regulation of new biomedical research technologies.
Subject(s)
Biomedical Research/legislation & jurisprudence , Research Personnel/legislation & jurisprudence , Technology, Pharmaceutical/legislation & jurisprudence , Animals , Humans , United StatesABSTRACT
Three-dimensional (3D) printing was discovered in the 1980s, and many industries have embraced it, but the pharmaceutical industry is slow or reluctant to adopt it. Spiritam® is the first and only 3D-printed drug product approved by FDA in 2015. Since then, the FDA has not approved any 3D-printed drug product due to technical and regulatory issues. The 3D printing process cannot compete with well-established and understood conventional processes for making solid dosage forms. However, pharmaceutical companies can utilize it where mass production is not required; rather, consistency, precision, and accuracy in quality are paramount. There are many 3D printing technologies available, and not all of them are amenable to pharmaceutical manufacturing. Each 3D technology has certain prerequisites in terms of material that it can handle. Some of the pertinent technical and regulatory issues are as follows: Current Good Manufacturing Practice, in-process tests and process control, and cleaning validation. Other promising area of 3D printing use is printing medications for patients with special needs in a hospital and/or pharmacy setting with minimum regulatory oversight. This technology provides a novel opportunity for in-hospital compounding of necessary medicines to support patient-specific medications. However, aspects of the manufacturing challenges and quality control considerations associated with the varying formulation and processing methods need to be fully understood before 3D printing can emerge as a therapeutic tool. With these points in mind, this review paper focuses on 3D technologies amenable for pharmaceutical manufacturing, excipient requirement, process understanding, and technical and regulatory challenges.
Subject(s)
Drug Industry/methods , Printing, Three-Dimensional/legislation & jurisprudence , Quality Control , Technology, Pharmaceutical/methods , Drug Delivery Systems/methods , Drug Industry/legislation & jurisprudence , Drug Industry/standards , Excipients/chemistry , Pharmacy Service, Hospital/legislation & jurisprudence , Pharmacy Service, Hospital/methods , Pharmacy Service, Hospital/standards , Technology, Pharmaceutical/legislation & jurisprudence , Technology, Pharmaceutical/standards , United States , United States Food and Drug Administration/legislation & jurisprudenceSubject(s)
Drug Design , Pharmaceutical Preparations/standards , Quality Control , Technology, Pharmaceutical , Guidelines as Topic , Legislation, Drug , Risk Assessment , Technology, Pharmaceutical/legislation & jurisprudence , Technology, Pharmaceutical/methods , Technology, Pharmaceutical/standardsABSTRACT
A calibration model for in-line API quantification based on near infrared (NIR) spectra collection during tableting in the tablet press feed frame was developed and validated. First, the measurement set-up was optimised and the effect of filling degree of the feed frame on the NIR spectra was investigated. Secondly, a predictive API quantification model was developed and validated by calculating the accuracy profile based on the analysis results of validation experiments. Furthermore, based on the data of the accuracy profile, the measurement uncertainty was determined. Finally, the robustness of the API quantification model was evaluated. An NIR probe (SentroPAT FO) was implemented into the feed frame of a rotary tablet press (Modul™ P) to monitor physical mixtures of a model API (sodium saccharine) and excipients with two different API target concentrations: 5 and 20% (w/w). Cutting notches into the paddle wheel fingers did avoid disturbances of the NIR signal caused by the rotating paddle wheel fingers and hence allowed better and more complete feed frame monitoring. The effect of the design of the notched paddle wheel fingers was also investigated and elucidated that straight paddle wheel fingers did cause less variation in NIR signal compared to curved paddle wheel fingers. The filling degree of the feed frame was reflected in the raw NIR spectra. Several different calibration models for the prediction of the API content were developed, based on the use of single spectra or averaged spectra, and using partial least squares (PLS) regression or ratio models. These predictive models were then evaluated and validated by processing physical mixtures with different API concentrations not used in the calibration models (validation set). The ß-expectation tolerance intervals were calculated for each model and for each of the validated API concentration levels (ß was set at 95%). PLS models showed the best predictive performance. For each examined saccharine concentration range (i.e., between 4.5 and 6.5% and between 15 and 25%), at least 95% of future measurements will not deviate more than 15% from the true value.
Subject(s)
Drug Compounding/methods , Models, Chemical , Spectroscopy, Near-Infrared/methods , Tablets/analysis , Technology, Pharmaceutical/legislation & jurisprudence , Calibration , Chemistry, Pharmaceutical , Drug Compounding/instrumentation , Excipients/analysis , Least-Squares Analysis , Spectroscopy, Near-Infrared/instrumentation , Technology, Pharmaceutical/instrumentationABSTRACT
Innovation in animal health pharmaceuticals is important to address unmet and underserved medical needs, and often comes from products initially developed for human medicine. The purpose of the review is to help readers understand how breakthroughs from human biotechnology may be developed for use in veterinary medicine, while understanding the key drivers to success, the difficulties of regulatory approval, and the realistic risks and rewards of developing applications for animals. The types of human drugs which may be useful for veterinary applications are reviewed, including examples. The regulatory path is discussed, with a review of the various oversight agencies, and the categories of data required to be submitted, including safety, efficacy, manufacturing, environmental impact and human food safety. In conclusion, the cost, development time, and barriers to innovation in veterinary medical pharmaceuticals are discussed.
Subject(s)
Legislation, Drug , Technology, Pharmaceutical/trends , Veterinary Drugs , Animal Welfare , Animals , Biotechnology , European Union , Food Safety , Humans , Technology, Pharmaceutical/legislation & jurisprudence , United States , United States Department of Agriculture , United States Environmental Protection Agency , United States Food and Drug AdministrationABSTRACT
Globally, there are few vitamin and mineral ingredient manufacturers. To support local, in-country or regional procurement and production of multiple micronutrient supplements (MMS), the following production scenarios are possible: (a) straight ingredients of vitamins and minerals forms imported or locally produced that are mixed, tableted, or encapsulated and packaged by a local manufacturer; (b) import or local production of a vitamin and minerals premix that is tableted or encapsulated and packaged locally; (c) import of a bulk, finished product (tablets or capsules) that is packaged and branded; and (d) or import of a branded packaged product. This paper is a situation analysis of the market, manufacturing, and policy factors that are driving the production of MMS in 12 lower and upper middle-income countries. Key informants completed a self-administered structured questionnaire, which examined the local context of products available in the market and their cost, regulations and policies, in Brazil, Colombia, Guatemala, Mexico, Peru, Bangladesh, India, Vietnam, Ghana, Kenya, Nigeria, and South Africa. Our study found that although most countries have the capacity to produce locally MMS, the major barriers observed for sustainable and affordable production include (a) poor technical capacity and policies for ensuring quality along the value chain and (b) lack of policy coherence to incentivize local production and lower the manufacture and retail price of MMS. Also, better guidelines and government oversight will be required because not one country had an MMS formulation that matched the globally recommended formulation of the United Nations Multiple Micronutrient Preparation (UNIMMAP).
Subject(s)
Dietary Supplements , Micronutrients , Nutrition Policy , Technology, Pharmaceutical , Developing Countries , Dietary Supplements/economics , Dietary Supplements/standards , Humans , Micronutrients/economics , Micronutrients/standards , Surveys and Questionnaires , Technology, Pharmaceutical/economics , Technology, Pharmaceutical/legislation & jurisprudence , Technology, Pharmaceutical/methods , Technology, Pharmaceutical/standardsABSTRACT
Post-authorisation safety studies (PASS) of vaccines assess or quantify the risk of adverse events following immunisation that were not identified or could not be estimated pre-licensure. The aim of this perspective paper is to describe the authors' experience in the design and conduct of twelve PASS that contributed to the evaluation of the benefit-risk of vaccines in real-world settings. We describe challenges and learnings from selected PASS of rotavirus, malaria, influenza, human papillomavirus and measles-mumps-rubella-varicella vaccines that assessed or identified potential or theoretical risks, which may lead to changes to risk management plans and/or to label updates. Study settings include the use of large healthcare databases and de novo data collection. PASS methodology is influenced by the background incidence of the outcome of interest, vaccine uptake, availability and quality of data sources, identification of the at-risk population and of suitable comparators, availability of validated case definitions, and the frequent need for case ascertainment in large databases. Challenges include the requirement for valid exposure and outcome data, identification of, and access to, adequate data sources, and mitigating limitations including bias and confounding. Assessing feasibility is becoming a key step to confirm that study objectives can be met in a timely manner. PASS provide critical information for regulators, public health agencies, vaccine manufacturers and ultimately, individuals. Collaborative approaches and synergistic efforts between vaccine manufacturers and key stakeholders, such as regulatory and public health agencies, are needed to facilitate access to data, and to drive optimal study design and implementation, with the aim of generating robust evidence.
Subject(s)
Adverse Drug Reaction Reporting Systems , Drug Industry/legislation & jurisprudence , Technology, Pharmaceutical/legislation & jurisprudence , Vaccines/adverse effects , Chickenpox Vaccine/adverse effects , Humans , Influenza Vaccines/adverse effects , Malaria Vaccines/adverse effects , Measles-Mumps-Rubella Vaccine/adverse effects , Papillomavirus Vaccines/adverse effects , Risk Assessment , Rotavirus Vaccines/adverse effects , Technology, Pharmaceutical/methods , Technology, Pharmaceutical/organization & administration , Vaccination , Vaccines/administration & dosage , Vaccines, Attenuated , Vaccines, Combined/adverse effectsABSTRACT
Currently, because globalization, the pharmaceutical industry is facing enormous challenges to comply with regulatory matters. Reduced patent life and overall decreased profitability of newly discovered drugs are also forcing the pharmaceutical industry to shorten the drug development time with maximum throughput. Therefore, continuous manufacturing (CM) processes via hot melt extrusion (HME) can be a promising alternative for achieving these goals. HME offers solvent-free green technology with a process that is easy to scale up. Moreover, CM provides better product quality assurance compared with batch processes, with fewer labor costs and shorter time to development. In this review, we primarily focus on various aspects of CM and the emerging application of HME to bridge the current manufacturing gap in pharmaceutical sphere.
Subject(s)
Technology, Pharmaceutical , Drug Industry/legislation & jurisprudence , Hot Temperature , Legislation, Drug , Technology, Pharmaceutical/legislation & jurisprudenceABSTRACT
Through its Global Action Plan for Influenza Vaccines (GAP), the World Health Organization (WHO) in collaboration with the United States Department of Health and Human Services has produced a checklist to support policy-makers and influenza vaccine manufacturers in identifying key technological, political, financial, and logistical issues affecting the sustainability of influenza vaccine production. This checklist highlights actions in five key areas that are beneficial for establishing successful local vaccine manufacturing. These five areas comprise: (1) the policy environment and health-care systems; (2) surveillance systems and influenza evidence; (3) product development and manufacturing; (4) product approval and regulation; and (5) communication to support influenza vaccination. Incorporating the checklist into national vaccine production programmes has identified the policy gaps and next steps for countries involved in GAP's Technology Transfer Initiative. Lessons learnt from country experiences provide context and insight that complement the checklist's goal of simplifying the complexities of influenza prevention, preparedness, and vaccine manufacturing.
Subject(s)
Developing Countries , Drug Industry/organization & administration , Influenza Vaccines/supply & distribution , Influenza, Human/prevention & control , Technology Transfer , Technology, Pharmaceutical/organization & administration , Drug Industry/economics , Government Programs/economics , Government Programs/organization & administration , Humans , Program Evaluation , Public Health , Technology, Pharmaceutical/economics , Technology, Pharmaceutical/legislation & jurisprudence , United States , United States Dept. of Health and Human Services , Vaccination , World Health OrganizationABSTRACT
Biosimilars are biotechnologically manufactured products that enter the market as and when the original biopharmaceutical goes off patent. As the name suggests, they are only "similar" and not exact versions of the originator product. The manufacturing process of biosimilars is complex, the product prone to variation, and regulatory approval rules are more extensive and elaborative than required for generic versions of chemically synthesized drugs. This makes the field of biosimilars interesting and inquisitive for research. As biosimilars are essentially protein drugs manufactured in living cells, immunogenicity becomes a major issue in almost all biopharmaceuticals. This increases the importance of Risk Management Plan (RMP) and pharmacovigilance. Since biosimilars are not identical copies of innovator products, the regulatory facets of indication extrapolation, automatic substitution, and interchangeability are more stringent than those available for small molecule generic drugs. This article discusses all these sectors significant to the world of biosimilars. Prospectively, biosimilars have the potential to deliver effective cost savings for healthcare users and thus they are a critical part of the biopharmaceutical industry.
Subject(s)
Biosimilar Pharmaceuticals/standards , Drugs, Generic/standards , Recombinant Proteins/standards , Technology, Pharmaceutical/methods , Biosimilar Pharmaceuticals/pharmacokinetics , Drug Monitoring/methods , Drug Monitoring/trends , Drugs, Generic/pharmacokinetics , Humans , Legislation, Drug , Pharmacovigilance , Technology, Pharmaceutical/legislation & jurisprudence , Therapeutic EquivalencyABSTRACT
This paper assesses the current regulatory environment, relevant regulations and guidelines, and their impact on continuous manufacturing. It summarizes current regulatory experience and learning from both review and inspection perspectives. It outlines key regulatory aspects, including continuous manufacturing process description and control strategy in regulatory files, process validation, and key Good Manufacturing Practice (GMP) requirements. In addition, the paper identifies regulatory gaps and challenges and proposes a way forward to facilitate implementation.
Subject(s)
Drug Industry/legislation & jurisprudence , Legislation, Drug , Pharmaceutical Preparations/chemical synthesis , Quality Control , Technology, Pharmaceutical/legislation & jurisprudence , Workflow , Consumer Product Safety , Drug Contamination/legislation & jurisprudence , Drug Contamination/prevention & control , Drug Industry/instrumentation , Drug Industry/methods , Drug Industry/standards , Drug Industry/trends , Equipment Contamination/legislation & jurisprudence , Equipment Contamination/prevention & control , Equipment Failure , Europe , Guidelines as Topic , Humans , Legislation, Drug/trends , Patient Safety , Pharmaceutical Preparations/standards , Technology, Pharmaceutical/instrumentation , Technology, Pharmaceutical/methods , Technology, Pharmaceutical/standards , Technology, Pharmaceutical/trends , United States , United States Food and Drug AdministrationABSTRACT
The report provides a summary of the presentations and discussions at the Virus & TSE Safety Forum 2013 organized by the Parenteral Drug Association (PDA) and held in Berlin, Germany, from June 4 to 6, 2013. The conference was accompanied by a workshop, "Virus Spike Preparations and Virus Removal by Filtration: New Trends and Developments". The presentations and the discussion at the workshop are summarized in a separate report that will be published in this issue of the journal as well. As with previous conferences of this series, the PDA Virus & TSE Safety Forum 2013 provided again an excellent opportunity to exchange information and opinions between the industry, research organizations, and regulatory bodies. Updates on regulatory considerations related to virus and transmissible spongiform encephalopathy (TSE) safety of biopharmaceuticals were provided by agencies of the European Union (EU), the United States (US), and Singapore. The epidemiology and detection methods of new emerging pathogens like hepatitis E virus and parvovirus (PARV 4) were exemplified, and the risk of contamination of animal-derived raw materials like trypsin was considered in particular. The benefit of using new sequence-based virus detection methods was discussed. Events of bioreactor contaminations in the past drew the attention to root cause investigations and preventive actions, which were illustrated by several examples. Virus clearance data of specific unit operations were provided; the discussion focused on the mechanism of virus clearance and on the strategic concept of viral clearance integration. As in previous years, the virus safety section was followed by a TSE section that covered recent scientific findings that may influence the risk assessment of blood and cell substrates. These included the realization that interspecies transmission of TSE by blood components in sheep is greater than predicted by assays in transgenic mice. Also, the pathogenesis and possibility of productive TSE infection of cell substrates were considered, and cell-based assays that may be suitable for use in TSE clearance studies were discussed. The current report provides an overview about the outcomes of the 2013 PDA Virus & TSE Safety Forum, a unique event in this field.
Subject(s)
Drug Contamination/prevention & control , Drug Industry/methods , Pharmaceutical Preparations/analysis , Prion Diseases/prevention & control , Technology, Pharmaceutical/methods , Virology/methods , Viruses/isolation & purification , Animals , Consumer Product Safety , Drug Contamination/legislation & jurisprudence , Drug Industry/legislation & jurisprudence , Humans , Infusions, Parenteral , Patient Safety , Policy Making , Prion Diseases/transmission , Technology, Pharmaceutical/legislation & jurisprudence , Virology/legislation & jurisprudenceABSTRACT
At one time, nearly all prescriptions were compounded preparations. There is an ongoing demand for compounded prescription medications because manufacturers cannot fulfill the needs of all individual patients. Compounding pharmacies are a long standing yet less frequently discussed element in the complex matrix of prescription drug manufacturing, distribution, and patient use. The drug shortage situation for many necessary and life-saving drug products is a complicating factor that has led to the numerous quality issues that currently plague large-scale compounding pharmacies. The states are the primary regulator of pharmacies, including community drug stores, large chains, and specialty pharmacies. Pharmacies making and distributing drugs in a way that is outside the bounds of traditional pharmacy compounding are of great concern to the U.S. Food and Drug Administration. The U.S. Congress has recently passed the Drug Quality and Security Act. This legislation establishes a clear boundary between traditional compounders and compounding manufacturers. It clarifies a national, uniform set of rules for compounding manufacturers while preserving the states' primary role in traditional pharmacy regulation. It clarifies the U.S. Food and Drug Administration's authority over the compounding of human drugs while requiring the Agency to engage and coordinate with states to ensure the safety of compounded drugs.
Subject(s)
Chemistry, Pharmaceutical/legislation & jurisprudence , Drug Compounding , Drug and Narcotic Control/legislation & jurisprudence , Health Policy/legislation & jurisprudence , Prescription Drugs , Technology, Pharmaceutical/legislation & jurisprudence , Chemistry, Pharmaceutical/standards , Drug Compounding/standards , Federal Government , Government Regulation , Guideline Adherence , Guidelines as Topic , Humans , Patient Safety , Prescription Drugs/standards , Risk Factors , State Government , Technology, Pharmaceutical/standards , United StatesABSTRACT
The introduction of the Quality-by-Design (QbD) initiative and of the Process Analytical Technology (PAT) framework by the Food and Drug Administration has opened the route to the use of systematic and science-based approaches to support pharmaceutical development and manufacturing activities. In this review we discuss the role that latent variable models (LVMs) can play in the practical implementation of QbD paradigms in the pharmaceutical industry, and the potential they may have in assisting the development and manufacturing of new products. The ultimate scope is to provide practitioners with a perspective on the effectiveness of the use of LVMs in any phase of the development of a pharmaceutical product, from its design up to its commercial production. After an overview of the main regulatory paradigms the QbD initiative is founded on, we show how LVMs can be feasibly used to support pharmaceutical development and manufacturing activities while matching the regulatory Agencies' requirements. Three main areas are identified, wherein the use of LVMs can provide significant benefits: (i) process understanding, (ii) product and process design, and (iii) process monitoring and control. For each of them, the main contributions recently appeared in the literature are reviewed. Issues open for further research are also identified.
Subject(s)
Models, Theoretical , Technology, Pharmaceutical/methods , Legislation, Drug , Quality Control , Technology, Pharmaceutical/legislation & jurisprudenceABSTRACT
This contribution provides an overview on the current legal requirements regarding limits for bromide and presents data on the actual bromide burden of commonly used herbal drugs. Evaluation of an extensive data base shows that results exceeding the limit of 50 mg/kg are found in specific plants which take up bromide to a high extent from the environment. Thus, positive findings of bromide in herbal drugs do not necessarily serve as a proof for methyl bromide treatment. Taking into account the ADI recommended by EMA and WHO, there are no toxicological concerns with regard to the intake of herbal teas, extracts or comminuted herbal drugs at therapeutic doses. Furthermore, the use of methyl bromide and other fumigants must be documented within the batch documentation. If stated in the batch documentation that no fumigation was carried out, it is not necessary to perform the test on bromide. In cases of a particular suspect and if toxicological concerns exist, additional testing can be performed in accordance with the limits set by Regulation (EC) No. 396/2005. For the above reasons, information obtained by performing the test on bromide is not significant for the assessment of quality. Therefore, it seems no longer necessary to maintain bromide in Ph. Eur. general chapter 2.8.13. Pesticide residues and it is recommended to delete it from Table 2.8.13.-1.